CACNA2D1

Voltage-dependent calcium channel subunit alpha-2/delta-1 · P54289 · CACNA2D1 on Sugi Atlas →

40,747 patent compounds predicted against CACNA2D1, 19,164 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL3502)	0.57	18/20
Bromide (SCHEMBL3377)	0.57	16/20
Oxalic Acid (SCHEMBL10154)	0.58	15/20
Hydrochloric Acid (SCHEMBL2587)	0.73	14/20
Oxalic Acid (SCHEMBL3993)	0.58	13/20
Oxalic Acid (SCHEMBL3799)	0.57	13/20
SCHEMBL770523	0.54	12/20
SCHEMBL94786	0.41	12/20
SCHEMBL116362	0.45	11/20
SCHEMBL539165	0.59	10/20
Hydrochloric Acid (SCHEMBL416268)	0.58	10/20
SCHEMBL770373	0.54	10/20
Phosphoric Acid (SCHEMBL3751)	0.52	10/20
SCHEMBL218912	0.47	10/20
SCHEMBL3592	0.76	9/20
SCHEMBL521176	0.76	9/20
SCHEMBL521869	0.76	9/20
SCHEMBL690970	0.63	9/20
SCHEMBL692061	0.63	9/20
SCHEMBL770497	0.53	9/20

Clinical trials — most relevant to CACNA2D1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Urine Concentration of S100B in Extremely Premature Infants	nan	COMPLETED
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
United States Hypophosphatasia Molecular Research Center	nan	COMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life	nan	COMPLETED
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias	nan	RECRUITING
Osteogenic Profiling of Normal Calvarial Bone	nan	COMPLETED
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Multidisciplinary Study of Right Ventricular Dysplasia	nan	COMPLETED
DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA2D1 binder may also engage these)

Protein	Name	Similarity
O08532	—	0.998	O08532 →
P13806	—	0.995	P13806 →
P54290	—	0.994	P54290 →
CACNA2D2	Voltage-dependent calcium channel subunit alpha-2/delta-2	0.983	landscape →
Q8CFG6	—	0.981	Q8CFG6 →
Q6PHS9	—	0.976	Q6PHS9 →
Q6PDJ1	—	0.956	Q6PDJ1 →
Q5VU97	—	0.950	Q5VU97 →
A1A4K5	—	0.950	A1A4K5 →
Q9HCM2	—	0.948	Q9HCM2 →
Q00960	—	0.948	Q00960 →
Q8BFR2	—	0.945	Q8BFR2 →
Q5NVB3	—	0.943	Q5NVB3 →
TRPM8	Transient receptor potential cation channel subfamily M member 8	0.943	landscape →
Q9EQH7	—	0.942	Q9EQH7 →
Q6EV76	—	0.942	Q6EV76 →
ENPP2	Autotaxin	0.942	landscape →
Q7TT15	—	0.941	Q7TT15 →
Q9R1E6	—	0.940	Q9R1E6 →
Q98864	—	0.940	Q98864 →
GRIN2B	Glutamate receptor ionotropic, NMDA 2B	0.940	landscape →
Q64610	—	0.939	Q64610 →
Q6GMK0	—	0.938	Q6GMK0 →
Q5R1P3	—	0.938	Q5R1P3 →
Q5BJZ6	—	0.938	Q5BJZ6 →
ITGB3	Integrin beta-3	0.937	landscape →
P18614	—	0.937	P18614 →
CSGALNACT1	Chondroitin sulfate N-acetylgalactosaminyltransferase 1	0.937	landscape →
Q4R854	—	0.937	Q4R854 →
Q9JHP7	—	0.937	Q9JHP7 →